Show newer
arawat

Non-Small Cell Lung Cancer Market

The Non-Small Cell Lung Cancer market is expected to increase with a CAGR of 10.7% during the study period of 2017-2030.
The total Non-Small Cell Lung Cancer incident cases were 484,726 in 7MM in 2017.

Increase use of biomarker testing, increase incidence of NSCLC, increase in the mutation specific trials activity & approval, and competitive landscape are some of the leading factors expected to drive the Non-Small Cell Lung Cancer market in the coming years.

The key players in Non-Small Cell Lung Cancer market include Novartis, Merck, KGaA, Eli Lilly and Company, Hoffmann-La Roche, Xcovery, BeyondSpring Pharmaceuticals, OSE Immunotherapeutics, Sanofi, Takeda, AbbVie and others.

For more detailed information visit: delveinsight.com/report-store/

0
arawat

Huntington’s Disease Market

Huntington disease (HD) is an autosomal-dominant neurodegenerative disease characterized by cognitive disturbance, motor abnormalities, and psychiatric symptoms. It is an orphan disease that is inherited genetically and results in a progressive breakdown of the nerve cells.

As per a study by Swierzewski et al. titled “Huntington’s Disease Overview, Incidence and Prevalence of HD,” 1 in every 10,000 persons (that accounts for nearly 30,00 people) in the United States are living with Huntington’s disease.
The rise in the prevalence of Huntington’s disease forms the major driving forces behind the advancing Huntington’s disease market.

Several companies such as Hoffmann-La Roche, EIP Pharma, Vaccinex, and SOM Biotech SL and others are in the process of developing multiple-stage products that have the potential to create a significant positive shift in the Huntington’s disease market Size.

For more details visit: delveinsight.com/blog/huntingt

0
arawat

Beta Thalassemia market

Each year thousands of infants are born afflicted with beta-thalassemia. Beta thalassemia is majorly prevalent in people from Mediterranean countries, North Africa, the Middle East, India, Central Asia, South Africa and Southeast Asia.

According to the Thalassemia International Federation, about 200,000 patients with thalassemia major are alive and registered as receiving regular treatment around the world.

Key players, such as Bluebird Bio, Protagonist Therapeutics, Acceleron Pharma, Sangamo Therapeutics, Sanofi, Fulcrum Therapeutics, Orchard Therapeutics and others are proactively working towards strengthening the beta-thalassemia market. The launch of various multiple-stage pipeline products will significantly revolutionize the β-thal market dynamics with the continuous efforts in research and development

For more detailed information visit: delveinsight.com/blog/beta-tha


thalassemia
@Beta thalassemia market
thalassemia Epidemiology

0
arawat

Small Cell Lung Cancer Market

The Small Cell Lung Cancer Market Size is Expected to Increase at a CAGR of 13.2% for the Study Period (2017-2030) in the 7MM.

The total incident cases of Small Cell Lung Cancer were 85,540 in 7MM IN 2017.

The key players in the Small Cell Lung Cancer Market include AstraZeneca, PharmaMar, EpicentRx, United Therapeutics, Ipsen, G1 Therapeutics, Otsuka Holdings, Takeda and others.

For more details visit:
delveinsight.com/report-store/



Cancer
Cancer Treatment

0
arawat

Will there be a second wave of coronavirus?

The Worldwide situation due to novel coronavirus, is getting worse with each passing day. To flatten the curve, countries around the world have adopted various unprecedented measures.

The preventive measures opted by the governments worldwide have somehow slowed down the pandemic transmission, but with the ease in restrictions recently the chances of the future waves look inevitable.

Just like the Spanish flu of 1918, it will not be wrong to expect a second wave of COVID19 too.
Until we have an effective vaccine, there is a constant risk of the second-wave or third-wave looming over the human race.

To read more visit:
delveinsight.com/blog/coronavi

0
arawat

Pulmonary Arterial Hypertension Market

According to DelveInsight, the market size of Pulmonary Arterial Hypertension in 7MM was found to be USD 4.6 Billion in 2017.

Among the 7MM, the United States accounts for the largest market size of Pulmonary Arterial Hypertension, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

The total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017.

The key players in the Pulmonary Arterial Hypertension market include United Therapeutics Corporation, Liquidia Technologies, Reata Pharmaceuticals, Altavant Sciences, Acceleron Pharma, PhaseBio Pharmaceuticals, Complexa, Arena Pharmaceuticals, Johnson & Johnson, GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc., Bayer AG, Pfizer, Bellerophon Pulse Technologies, and many others.

For more information visit:
delveinsight.com/report-store/

0
arawat

Acute Kidney Injury Market

The market size of Acute Kidney Injury in the United States was USD 2,907 Million in 2017.

The United States recorded 895,078 cases of Acute Kidney Injury in 2017, while Germany had registered around 82,902 diagnosed cases during the same period.

The key companies in the Acute Kidney Injury market include Exponential Biotherapies, Alloksys, Angion Biomedica Corp, Quark Pharmaceuticals, AM Pharma, Atox Bio, Astellas Pharma, Orion Pharma, MediBeacon, Pharming and others.

For more detailed information visit at: delveinsight.com/report-store/


0
arawat

Rise of Telehealth

Telehealth includes a wide variety of healthcare services apart from the doctor-patient interaction such as health administration, patient and professional health-related education, public health monitoring, long-distance clinical healthcare, administrative meetings, and training etc.

A large number of hospitals, private tech players are showing interest in telehealth services. Some of the leading companies advancing telehealth services facilitating their use by common people include Zipnosis, Philips, Polycom, Doctor On Demand, Amwell, MDLIVE, Inc., Sherpaa and others.

For more details visit:
delveinsight.com/blog/opportun

0
arawat

Non-small cell lung cancer Market

The total Non-small cell lung cancer incident cases in the 7MM were observed to be 484,726 cases in the year 2017.
Non-Small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030.

Key players such as AstraZeneca, Bristol Myers Squibb, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda, Eli Lilly and Company, Johnson & Johnson, Sanofi, GSK, along with others are driving the non-small cell lung cancer market forward.

For more details visit:
delveinsight.com/blog/non-smal

0
arawat

Ovarian Cancer market

Ovarian cancer is the seventh most common form of cancer and the eighth leading cause of deaths in women in the world.
In 2018, there were approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States.

The launch of potential emerging therapies such as OTL38 (On Target Laboratories), 2X-121 (Oncology Venture), PX-Survivac (IMMUNOVACCINE INC), Oregovomab (OncoQuest Inc.), HPN536 (Harpoon Therapeutics), Mirvetuximab soravtansine (IMGN853, ImmunoGen, Inc.) and PRGN-3005 UltraCAR-T (Precigen) are expected to change the treatment landscape of ovarian cancer in the coming years.

For more details visit:
delveinsight.com/blog/ovarian-

0
arawat

Open-Angle Glaucoma Market

Open-Angle Glaucoma Market Size in the 7MM was found to be USD 3,316.71 million in 2017.
The total prevalent population of Glaucoma in the 7MM was 9,819,080 in 2017.

Rich Emerging Pipeline, Development of Advanced Antiglaucoma Medications, Patient-Friendly Dosage Regimes, Rise in Awareness, and Development of Treatment Methods to Tackle the Situation of Non-Adherence are the Open-Angle Glaucoma market drivers.

Some of the key players in Open-Angle Glaucoma Market include Peregrine Ophthalmic, Ocuphire Pharma, Envisia Therapeutics, Sylentis S.A., Nicox Ophthalmics, Chong Kun Dang Pharmaceutical Corp, Santen Pharmaceutical, Sofia Labs, LLC, Sun Pharma Advanced Research, Allergan, Ocular Therapeutix, and others.

For more detailed information visit:
delveinsight.com/report-store/

0
arawat

Duchenne Muscular Dystrophy Market

The market size of Duchenne Muscular Dystrophy in the 7MM was found to be USD 266.06 Million in 2017. The United States accounts for the largest Duchenne Muscular Dystrophy (DMD) market size in comparison to EU5 and Japan.
The total diagnosed DMD prevalent population in 2017 was 27,685 (in 7MM).

The key players in Duchenne Muscular
Dystrophy Market include Sarepta Therapeutics, Santhera Pharmaceuticals, Italfarmaco, Catabasis Pharmaceuticals, NS Pharma, Pfizer, Taiho Pharmaceutical, FibroGen, Daiichi Sankyo, Nobelpharma, and many others.

For more details visit: delveinsight.com/report-store/

0
arawat

Hidradenitis Suppurativa Market

The therapeutic market of Hidradenitis Suppurativa in the 7MM was USD 718.3 Million in 2017.
In 2017, the total prevalent population of Hidradenitis Suppurativa was 6,851,308 in 7MM.

The Market drivers of Hidradenitis Suppurativa are
1. Growing Prevalent Patient Pool
2. Increasing awareness of the disease
3. Improvement in healthcare economy and affordable treatment options
The key players in Hidradenitis Suppurativa market include InflaRx, Novartis Pharmaceuticals, ChemoCentryx, AbbVie and others.

For more detailed information visit: delveinsight.com/report-store/

0
arawat

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Market Size of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia in the 6MM is expected to be USD 1,315.7 Million in 2030.

Among the EU-5 countries, Germany, France, Italy accounts for the highest market size for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia followed by the UK and Spain.

Advancement in technology, increased collaboration & acquisition, and competition among biotech & pharma giants are some of the leading factors expected to drive the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia market in the coming years.

The key companies in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia market include Autolus Therapeutics, Precision BioSciences, Novartis, Miltenyi Biotec and others.
For more detailed information visit:
delveinsight.com/report-store/

0
arawat

Chronic Inflammatory Demyelinating Polyneuropathy Market

Market Size of Chronic Inflammatory Demyelinating Polyneuropathy in the 7MM was found to be 1194.55 Million in 2017.

The total prevalent population of Chronic Inflammatory Demyelinating Polyneuropathy in 7MM countries was estimated to be 44,843 in 2017.

Rising Prevalence and Awareness, Advanced Technologies, Increasing R&D Activities are some of the leading factors expected to drive the Chronic Inflammatory Demyelinating Polyneuropathy market in the coming years.
The key players in the Chronic Inflammatory Demyelinating Polyneuropathy market include Teijin Pharma, OctaPharma, Shire, Takeda, Momenta Pharmaceuticals, LFB Group, MedDay Pharma and others.

For more detailed information visit: delveinsight.com/report-store/

0
arawat

Chemotherapy Induced Febrile Neutropenia Market
Neutropenia is one of the most severe hematologic toxicities of cancer chemotherapy and often limits the doses of chemotherapy tolerated by the patients. It is a condition that results in a low neutrophil count in the blood, thus rendering the patient susceptible to infections from pathogens, ultimately leading to fever – in the case known as Chemotherapy Induced Febrile Neutropenia (CIFN).
Febrile neutropenia one of the most common and adverse complications of chemotherapy, which in addition to reduced immunity, also delays the course of treatments, leads to early termination of the doses and compromises with the potential of curing the patient.
Rolontis (Spectrum Pharmaceuticals, Inc.), Fulphila (Mylan), Udenyca (Coherus BioSciences), Mosedipimod (Enzychem Lifesciences ), Pelmeg (CINFA), Ziextenzo (Sandoz), Myelo001 (Myelo Therapeutics GmbH), ALRN-6924 (Aileron Therapeutics) along with Neulasta including MYL-1401H (Mylan), CHS-1701 (Coherus BioSciences), B12109 (CINFA) and LA-EP2006 (Sandoz) are anticipated to impact Chemotherapy-Induced Febrile Neutropenia market positively in the coming years.

For more details visit:
delveinsight.com/blog/chemothe

0
arawat

Chronic Lower Back Pain (CLBP) Market

The market size of Chronic Lower Back Pain in the 7MM is expected to grow at a CAGR of 3.55% for the study period, 2017– 2030.
Among the 7MM countries, the United States had the highest market size of Chronic lower back pain (CLBP) in 2017, which accounts for approximately 62.18% of the total market.

In 2017, the total Prevalent Population of Chronic lower back pain (CLBP) in the 7MM was found to be 73,802,461.

The key players in Chronic Lower Back Pain (CLBP) Market includes Braeburn Pharmaceuticals, Camurus, Regeneron Pharmaceuticals, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, Egalet Corporation, Axsome Therapeutics, Allodynic Therapeutics, Astellas Pharma, Grünenthal GmbH, Frontier Biotechnologies, DiscGenics, Yuhan Corporation, Semnur Pharmaceuticals, Sollis Therapeutics, SpineThera, Stayble Therapeutics, AnGes MG and many others.

For more detailed information visit:
delveinsight.com/report-store/

0
arawat

Neoantigen based Personalized Cancer Therapeutic Vaccines Market

Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body’s immune system to fight cancer.
Neoantigens are non-autologous proteins which are specific to individuals and are a result of non-synonymous mutations in the tumor cell genome.

Bioinformatics-technological advancements, improved diagnosis, and a strong pipeline are some of the factors contributing to the advancement of Neoantigen based Personalized Cancer Therapeutic Vaccines Market.
Several key players such as Gradalis, OSE Immunotherapeutics, Immunitor, Gritstone Oncology, Genocea, Targovax, Hangzhou Neoantigen Therapeutics, Neon Therapeutics along with many others are robustly involved in fuelling Neoantigen-based Personalized Cancer therapeutic Vaccines market.

For more details visit: delveinsight.com/blog/neoantig

0
arawat

COVID-19 Diagnostic Projects

The rapid spread of Coronavirus has put the healthcare agencies in a perilous position as they are running out of the diagnostics kits.

To deal with the current situation, governments and companies around the world are working in collaboration to fulfil the current COVID-19 diagnostics demand.
Globally a large number of diagnostic projects are going on to boost testing for covid19.

Some of the projects such as Northwestern University’s One step diagnostic tool, LabCorp’s at home COVID19 test kit, Innovative Genomics Institute's automated COVID-19 Diagnostic Testing and many others are likely to make a significant contribution to COVID-19 detection in coming weeks.

For more details visit:
delveinsight.com/blog/covid-19

0
arawat

Copper Kills Coronavirus

The viruses and other micro-organisms have a longer life-span on some surfaces compared with others. Similarly, novel coronavirus -SARS-CoV-2 lives longer on some surfaces than others.

According to a paper published in The New England Journal of Medicine (NEJM), which evaluated the stability of SARS-CoV-2 in aerosols and other surfaces, estimated that SARS-CoV-2 was able to persist more on plastic and stainless steel than on copper and cardboard.

Scientists are now examining the antimicrobial property of copper for preventing and controlling the transmission of SARS-CoV-2.

For more details visit:
delveinsight.com/blog/novel-co

0
Show older
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.

Trending now

Resources

Developers

What is Mastodon?

qoto.org

More…

v3.5.19-qoto · Privacy policy